Investigation into the radiobiological consequences of pre-treatment verification imaging with megavoltage X-rays in radiotherapy


Published in:
British Journal of Radiology

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
Copyright 2014 the authors.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and/or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Investigation into the radiobiological consequences of pre-treatment verification imaging with megavoltage X-rays in radiotherapy

W B HYLAND, PhD, S J MCMAHON, PhD, K T BUTTERWORTH, PhD, A J COLE, MB BCH, MRCP, R B KING, PhD, K M REDMOND, PhD, K M PRISE, PhD, A R HOUNSELL, PhD and C K MCGARRY, PhD

1Radiotherapy Physics, Northern Ireland Cancer Centre, Belfast Health and Social Care Trust, UK
2Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, UK
3Clinical Oncology, Northern Ireland Cancer Centre, Belfast Health and Social Care Trust, UK

Address correspondence to: Dr Wendy Bridget Hyland
E-mail: wendy.hyland@belfasttrust.hscni.net

Objective: The aim of this study was to investigate the effect of pre-treatment verification imaging with megavoltage X-rays on cancer and normal cell survival in vitro and to compare the findings with theoretically modelled data. Since the dose received from pre-treatment imaging can be significant, the incorporation of this dose at the planning stage of treatment has been suggested.

Methods: The impact of imaging dose incorporation on cell survival was investigated by clonogenic assay of irradiated DU-145 prostate cancer, H460 non-small-cell lung cancer and AGO-1522b normal tissue fibroblast cells. Clinically relevant imaging-to-treatment times of 7.5 and 15 min were chosen for this study. The theoretical magnitude of the loss of radiobiological efficacy due to sublethal damage repair was investigated using the Lea-Catcheside dose protraction factor model.

Results: For the cell lines investigated, the experimental data showed that imaging dose incorporation had no significant impact on cell survival. These findings were in close agreement with theoretical results.

Conclusion: For the conditions investigated, the results suggest that allowance for the imaging dose at the planning stage of treatment should not adversely affect treatment efficacy.

Advances in knowledge: There is a paucity of data in the literature on imaging effects in radiotherapy. This article presents a systematic study of imaging dose effects on cancer and normal cell survival, providing both theoretical and experimental evidence for clinically relevant imaging doses and imaging-to-treatment times. The data provide a firm foundation for further study into this highly relevant area of research.

Radiotherapy is in a period of rapid scientific and clinical development. With the introduction of adaptive radiotherapy and the increasing use of high-precision techniques, there has been an increased requirement for verification imaging. Verification imaging can be carried out using megavoltage portal beams, kilovoltage planar fields or cone beam CT (CBCT) using kilovoltage or megavoltage beams. Dependent on the imaging technique employed, the dose required to acquire an image of adequate quality can vary significantly. Whilst doses ranging from a few centigrays to 10 cGy are required for megavoltage portal imaging and CBCT, doses in the order of megagrays are typically required to obtain an image of adequate quality using kilovoltage planar imaging. The choice of imaging modality is dictated by the available technology, with megavoltage portal imaging being the most established imaging option. However, with the addition of on-board kilovoltage imaging systems, kilovoltage imaging options are becoming much more widespread both for their improved image contrast and reduced patient dose.

Associated with this increasing imaging dose burden are concerns regarding the increased risk of deterministic and stochastic effects due to increased radiation exposure. Whilst it is important to quantitatively determine the long-term effects of increased concomitant exposures, it is equally important to determine any potential changes to the effectiveness of the therapeutic dose.

Low-dose biological phenomena such as adaptive responses and bystander signalling hold the potential to significantly alter the response of cells to radiation and thus treatment efficacy. However, since these effects tend to occur over a period of hours, it is unlikely that they will have any significant impact with regard to imaging in the
treatment room. By contrast, sublethal damage repair that can occur over a period of minutes may be of significance in radiotherapy when the dose delivered from imaging beams is incorporated with the prescribed therapeutic dose at the treatment planning stage.

The effect of imaging dose incorporation was previously reported in a preliminary study by Yang et al. In particular, they showed an unexpected 12.6% increase in cell survival when H460 cells were exposed to a pre-treatment imaging dose of 5 cGy followed by a therapeutic dose of 200 cGy, they attributed

<table>
<thead>
<tr>
<th>Treatment type</th>
<th>$\tau_{I-T} \pm SD$ (min)</th>
<th>Upper 95% CI ($\tau_{I-T}$)</th>
<th>OTT $\pm SD$ (min)</th>
<th>Upper 95% CI (OTT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMRT</td>
<td>8.56 ± 3.62</td>
<td>15.67</td>
<td>14.93 ± 4.4</td>
<td>23.55</td>
</tr>
<tr>
<td>3DCRT</td>
<td>8.18 ± 5.25</td>
<td>18.48</td>
<td>11.48 ± 5.62</td>
<td>22.48</td>
</tr>
</tbody>
</table>

CI, confidence interval; SD, standard deviation associated with the calculated values.

Figure 1. (a) An image of the irradiation set-up. (b) A schematic representation of the experimental set-up. The cells were irradiated at 4.8 cm deep in a custom-made polymethyl methacrylate phantom, with 5 cm of backscatter. (Inset) the dose profile across the three flasks at the cell level, acquired using a two-dimensional matrix ion chamber array at an effective depth of 5 cm.
their findings to increased cell proliferation. The results suggest that the delivery of a fraction of the therapeutic dose by imaging beams presents a potential issue since the time from imaging to delivery of the treatment can be of the order of 5–20 min, having a negative impact on treatment efficacy owing to low-dose biological phenomena or sublethal damage repair that may be initiated during this time. Although the need for imaging dose incorporation is justified, the potential to affect treatment efficacy should be determined.

To investigate the radiobiological impact of imaging dose incorporation, a series of experiments were conducted in vitro, where the imaging doses were incorporated with the prescribed treatment dose for different human cell lines. As megavoltage portal imaging is the most widely used type of imaging for verification and as it delivers a higher dose, the study was carried out using 6 MV beams for both the imaging and treatment components. The theoretical magnitude of this effect and its impact on cell survival was quantified using radiobiological modelling based on the Lea–Catcheside dose protraction factor as a comparison to the experimental data.

**METHODS AND MATERIALS**

**Clinical audit**

Using the Varian offline review program (Varian Medical Systems, Inc., Palo Alto, CA), an analysis of the time taken between the acquisition of a pre-treatment verification image and the treatment delivery was carried out for 30 patients for prostate and pelvic node intensity-modulated radiotherapy (IMRT) and 30 prostate patients for three-dimensional conformal radiotherapy (3DCRT), who were undergoing treatment at the Northern Ireland Cancer Centre (Belfast, UK). The time between the acquisition of the first megavoltage portal image and treatment was recorded as the overall treatment time (the average time from the acquisition of the first megavoltage portal image to the end of the treatment). The results are presented in Table 1. For the IMRT and 3DCRT patient groups, a total of 106 and 101 treatment fractions were analysed, respectively. From these data, image-to-treatment times of 7.5 and 15 min were chosen for this study, as they were considered to be broadly representative of the average and upper extreme values of this data set. These values are consistent with typical imaging-to-treatment times of 5–20 min that have been reported previously.

**Cell culture**

Experiments were conducted using the human prostate cancer cell line DU-145 and the human non-small-cell lung cancer cell line H460, obtained from the American Type Culture Collection (Teddington, UK). Both cancer cell lines were grown in RPMI-1640 with L-glutamine (Lonza, Cambridge, UK), supplemented with 10% foetal bovine serum and 1% penicillin/streptomycin (Gibco, Paisley, UK). The human tissue fibroblast cell line (AG0-1522b) cells were purchased from the Coriell Institute for Medical Research.
Institute for Medical Research (Camden, NJ) and grown in Eagle's minimum essential medium with deoxyribonucleosides and deoxyribonucleotides (Lonza), supplemented with 20% foetal bovine serum and 1% penicillin/streptomycin. All cell lines were maintained at 37°C in an atmosphere of 5% CO₂ in air and 95% humidity.

Clonogenic assay
The effect of radiation on cell viability was investigated using the clonogenic assay. All cells were plated 18–24 h prior to exposure. The DU-145 and H460 cells received doses of 2, 4 or 8 Gy, whereas the more radiosensitive AGO-1522b cells received doses of 1, 2 or 4 Gy. Prior to irradiation, the culture flasks were completely filled with RPMI-1640 incomplete media to ensure full scatter conditions. Irradiations were conducted at room temperature (25 ± 2°C). All exposures were conducted in triplicate on at least three independent occasions. For all experiments, six unexposed controls were prepared and sham irradiated. After exposure, the incomplete media was removed from the flasks and replaced with 5 ml of RPMI-1640 complete media. The cells were subsequently incubated for 8–12 days at 37°C, in an atmosphere of 5% CO₂ in air and 95% humidity. At the appropriate time, the cells were stained with 0.5% crystal violet in 50% methanol. Cell colonies were scored manually using the 50-cell exclusion criterion.

Irradiation set-up and in vivo experimental design
A monolayer of cells was irradiated in T25 culture flasks with 6 MV X-rays produced by a TrueBeam™ LINAC (Varian Medical Systems, Inc.) under a uniform beam (Figure 1a). Three T25 flasks were irradiated simultaneously. The cells were separated by a distance of 100 cm from the X-ray source, for a field size of 20 × 20 cm (at 100 cm). A schematic representation of the experimental set-up is shown in Figure 1b.

Investigations were conducted to determine the effect of combining a pre-treatment imaging dose of 5 cGy with a variable therapeutic dose to deliver total doses of 2, 4 or 8 Gy for DU-145 and H460 cells or 1, 2 or 4 Gy for the AGO-1552b cells. The delivery of the two parts of the total dose was separated by times of 7.5 or 20 cm (at 100 cm). A schematic representation of the two irradiation groups—standard and split dose. The standard group received the prescribed dose (D₂) in a single irradiation, delivered at 400 monitor units (MU) min⁻¹; whereas, the split-dose group received the prescribed dose in two time-delayed irradiations. Specifically, the first irradiation delivered a dose of 5 cGy at 100 MU min⁻¹ to the cells (representing a pre-treatment imaging dose) and the second irradiation delivered the remainder of the total dose prescribed, at a dose rate of 400 MU min⁻¹.

Dosimetric verification
Dosimetry measurements were performed using a Farmer® ionization chamber (NE-Technology Ltd, Reading, UK) at a radiological equivalent depth to the cell position with a calibration traceable to the National Physical Laboratory, in accordance with the Institute of Physical Sciences in Medicine 1990 code of practice. As a further verification of the ionization chamber measurements, a series of CT images of the polymethyl methacrylate phantom containing the culture flasks were taken with a GE LightSpeed® CT scanner (GE Healthcare, Chalfont St Giles, UK). The CT data set was sent from the CT scanner to the Eclipse™ (Varian Medical Systems, Inc.) treatment planning system where the prescription point was positioned at the cell level, at the centre of the middle flasks and a 6 MV 20 × 20 cm² field planned to deliver a prescription dose of 2 Gy. The number of monitor units required to deliver the prescribed dose was found to be in agreement with the dose determined using the ionization chamber reading to within ±1%. The dose variation between the three flasks irradiated at the same time was <1%.

Experimental data analyses
The fraction of cells surviving after treatment was calculated as the ratio of the number of colonies in the exposed flask to the number of cells seeded, corrected for the plating efficiency of the sham-irradiated controls. The standard error associated with each data point was calculated. The data were subsequently plotted using Origin Pro v. 8 (Origin Lab, Northampton, MA) and fitted to the linear quadratic equation for single acute doses: survival fraction = 𝑒−(α+βD), where D is the total dose and α and β are tissue-specific parameters. The fits were weighted by 1/(variance of each data point). F-tests were carried out to determine if any differences in the fits to the data sets were

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Definition</th>
<th>DU-145</th>
<th>H460</th>
<th>AGO-1522b</th>
</tr>
</thead>
<tbody>
<tr>
<td>Δ𝑡₁</td>
<td>Imaging time</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Δ𝑡₂</td>
<td>Treatment time</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>D₁</td>
<td>Total dose (Gy)</td>
<td>2, 4 or 8</td>
<td>2, 4 or 8</td>
<td>1, 2 or 4</td>
</tr>
<tr>
<td>D₂</td>
<td>Imaging dose (Gy)</td>
<td>0.05</td>
<td>0.05</td>
<td>0.05</td>
</tr>
<tr>
<td>D₃</td>
<td>Therapeutic dose rate (Gy min⁻¹)</td>
<td>4</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>D₄</td>
<td>Imaging dose rate (Gy min⁻¹)</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>R₀/₂</td>
<td>Repair half-time (min)</td>
<td>16</td>
<td>90</td>
<td>130</td>
</tr>
<tr>
<td>τ₀/₂</td>
<td>Imaging-to-treatment time (min)</td>
<td>7.5 or 15</td>
<td>7.5 or 15</td>
<td>7.5 or 15</td>
</tr>
</tbody>
</table>
The dose protraction factors

Theoretical data

AGO-1552b, and 15-min split dose curves (DU-145, moreover, no signiﬁcantly when it was part delivered by a 6 MV imaging beam (100 MU min⁻¹), either 7.5 or 15 min prior to delivery of the remainder of the prescribed dose by a 6 MV treatment beam (400 MU min⁻¹). By integration of the Lea–Catcheside dose protraction factor [G(Δt)]², which is based on an assumed mono-exponential pattern of sublethal damage recovery and takes account of the imaging and treatment doses, the protracted exposure time and the time gap between imaging and treatment delivery, the following Equation (1) is obtained:

\[
G[D_i(\Delta t_i) + T] = \frac{1}{(D_i \Delta t_i + D_i \Delta t_i + T)} \left[ \left( D_i \Delta t_i \right)^2 \gamma(\mu \Delta t_i) + \frac{2 D_i \Delta t_i}{\mu} e^{-\mu \Delta t_i} \left( 1 - e^{-\mu \Delta t_i} \right) \left( 1 - e^{-\mu \Delta t_i} \right) + \left( D_i \Delta t_i \right)^2 \gamma(\mu \Delta t_i) \right]^{1/2}
\]

(1)

Where \( \mu = \ln(2)/R_{1/2} \) and \( (\mu \Delta t_i) = 2 \mu \Delta t_i + e^{-\mu \Delta t_i} - 1/(\mu \Delta t_i)^2 \), where \( \Delta t_i \) is the duration of the exposure. The definitions of the individual parameters contained within this equation are presented in Table 2. Using the experimentally determined \( \alpha \) and \( \beta \) values for each cell line, the calculated dose protraction factor \( G \) was subsequently incorporated into the linear quadratic model \[ \text{Surviving fraction} = e^{-\left(\alpha D + 0.57 \beta D^2\right)} \] to calculate cell survival. From the modelled data of cell survival, an effective dose was then calculated to determine the dose required to achieve the same level of cell kill if the dose was delivered in a single fraction.

RESULTS

Experimental data

Figure 3 shows the survival curves generated for DU-145, H460 and AGO-1552b cells for the standard-dose, split-dose (\( \tau_{s-t} = 7.5 \) min and \( \tau_{s-s} = 15 \) min cases. The determined \( \alpha \) and \( \beta \) values for each cell line for each combination of irradiation conditions are presented in Table 3. Analysis did not show any statistically signiﬁcant differences between the control curve vs the 7.5-min split-dose curve for each cell line (DU-145, \( p = 0.53 \); H460, \( p = 0.32 \); AGO-1552b, \( p = 0.35 \)) or the control curve vs the 15-min split-dose curve (DU-145, \( p = 0.39 \); H460, \( p = 0.27 \); AGO-1552b, \( p = 0.37 \)). Moreover, no signiﬁcant differences were found between the 7.5- and 15-min split dose curves (DU-145, \( p = 0.58 \); H460, \( p = 0.28 \); AGO-1552b, \( p = 0.36 \)).

Theoretical data

The dose protraction factors \[ G[D_i(\Delta t_i) + T] \] were calculated for each dose and each imaging-to-treatment times investigated for the DU-145, H460 and AGO-1552b cells. The parameter values used to calculate \[ G[D_i(\Delta t_i) + T] \] are presented in Table 2. Taken from the literature, repair half-times of 16, 90 and 130 min were used for DU-145, H460 and AGO-1552b cells, respectively.\(^{21,27,28}\) The calculated values were incorporated into the linear quadratic model to calculate the corresponding surviving fractions. The
instant effect was also calculated using the formula: 

\[ \text{surviving fraction} = e^{- (\alpha D + \beta D^2)} \] 

for each dose, i.e. the effect when the dose was delivered in a single irradiation by the treatment beam (400 MU min\(^{-1}\)). As a comparison, the generated surviving fraction data for the split-dose treatments were used to calculate the protracted effective dose for each dose point, i.e. the dose required to cause the same level of cell kill if the dose was delivered in a single fraction.

The calculated surviving fractions for imaging-to-treatment times of 7.5 and 15 min for DU-145, H460 and AGO-1552b cells are presented in Table 4. The data were subsequently plotted and fitted using the linear quadratic model, although data were not presented as overlaid curves. The theoretical results are in good agreement with the experimental data presented previously. Currently, dose incorporation is rarely implemented owing to the practical difficulties of calculating imaging dose and summing this with the treatment dose, as well as the uncertainty of repeat exposures during treatment to ensure set-up accuracy. Hence, the modelling was used to determine the effect of not incorporating the dose into the plan. Table 5 shows that the protracted effective dose was lower than the prescribed instant effect for the DU-145 cells delivering 8 Gy.

**DISCUSSION**

In the era of high-precision conformal and adaptive radiotherapy, the use of imaging in the treatment room is set to increase. Since the dose received from pre-treatment verification imaging can be considerable, it has been suggested that the dose should be accounted for at the treatment planning stage. Although this allows for the correct calculation of normal tissue and tumour dose, imaging dose incorporation has the potential to impact the treatment efficacy in an adverse manner. This is because in the time between pre-treatment imaging and delivery of the remaining treatment dose, sublethal damage repair may occur, which may lead to a reduced amount of sublethal damage that can be subsequently compounded to lethal damage by the treatment dose. In turn, this has the potential to result in an increase in the surviving fraction of cells after treatment.

The aim of this research was to investigate the impact of imaging dose incorporation on cell survival in vitro, in both human cancer and normal tissue cell lines. The results from the experimental studies presented here reveal that imaging dose incorporation has no significant impact on cell survival, for clinically relevant imaging-to-treatment times of 7.5 or 15 min for all cell lines investigated. Results from DU-145 cells support the results from related studies by Butterworth et al and McGarry et al, who reported no statistically significant trends towards increased cell survival in DU-145 cells for prolonged treatment delivery times. AGO-1522b cells have shown some dose rate effects for non-modulated beams, but no effects were observed in this study. The results for H460 cells are in clear disagreement with the preliminary experimental findings of Yang et al, who reported a 12.6% (p < 0.02) increase in cell survival when a 5-cGy pre-treatment imaging dose was delivered to the cells prior to the delivery of a therapeutic dose of 200 cGy. However, the details of the experimental protocol used and specific results of this study by Yang et al remain unpublished. Bewes et al investigated the impact of prolonged treatment delivery times on cell survival. They reported that as the time taken to deliver a specified dose of radiation increased, a corresponding increase in cell survival was observed for a melanoma cell line (MM576) and for H460 cells. The study by Bewes et al highlights that extended treatment times may significantly impact tumour control in an adverse manner; however, these experiments were undertaken for continuous dose irradiation, whereas the study reported herein is for a split-dose irradiation scenario.

The experimental data presented for AGO-1522b, DU-145 and H460 cells were found to be in excellent agreement with the theoretically determined data, which was modelled using the Lea–Catcheside dose protraction factor. These results are encouraging, as the imaging-to-treatment times used are of clinical relevance. Furthermore, in terms of effective dose (i.e. the dose required to achieve the same level of cell kill if the dose was delivered in a single irradiation), the largest percentage difference was found to be 1.37%. From both the experimental and theoretical data presented here, incorporation of an imaging dose of 5 cGy with a prescribed treatment dose, for imaging-to-treatment times not exceeding 15 min, would not be expected to impact tumour control in an adverse manner since no significant change in cell survival is observed. These findings are in agreement with the theoretical study of Flynn who reported that the loss of radiobiological efficiency due to sublethal damage repair, when imaging doses are incorporated with the treatment dose, is clinically insignificant if the imaging dose delivered is ≤5% of the total dose, or if the delay time between imaging and treatment is in the order of 5 min.

Although sublethal damage repair is a key player in the context of the research presented here, other biological effects such as adaptive responses and bystander effects may become more influential as radiotherapy techniques and delivery options become more sophisticated.

---

**Table 3. Calculated α and β values for the three cell lines investigated**

<table>
<thead>
<tr>
<th>Experimental group</th>
<th>DU-145</th>
<th>H460</th>
<th>AGO-1552b</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>α</td>
<td>β</td>
<td>α</td>
</tr>
<tr>
<td>Control</td>
<td>0.08 ± 0.04</td>
<td>0.02 ± 0.01</td>
<td>0.256 ± 0.06</td>
</tr>
<tr>
<td>7.5 min</td>
<td>0.03 ± 0.03</td>
<td>0.03 ± 0.01</td>
<td>0.273 ± 0.05</td>
</tr>
<tr>
<td>15 min</td>
<td>0.08 ± 0.04</td>
<td>0.02 ± 0.01</td>
<td>0.248 ± 0.05</td>
</tr>
</tbody>
</table>

Data presented as mean ± standard deviation.
Table 4. Instant vs protracted effect for DU-145, H460 and AGO-1522b cells incorporating the dose into the plan.

<table>
<thead>
<tr>
<th>Instant effect dose</th>
<th>Imaging dose (Gy)</th>
<th>Treatment dose (Gy)</th>
<th>DU-145</th>
<th>H460</th>
<th>AGO-1522b</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Protracted effective dose</td>
<td>Difference (%)</td>
<td>Protracted effective dose</td>
<td>Difference (%)</td>
<td>Protracted effective dose</td>
</tr>
<tr>
<td>1</td>
<td>0.05</td>
<td>0.95</td>
<td>–</td>
<td>–</td>
<td>1.00</td>
</tr>
<tr>
<td>2</td>
<td>0.05</td>
<td>1.95</td>
<td>1.99</td>
<td>−0.52</td>
<td>2.00</td>
</tr>
<tr>
<td>4</td>
<td>0.05</td>
<td>3.95</td>
<td>3.97</td>
<td>−0.70</td>
<td>4.00</td>
</tr>
<tr>
<td>8</td>
<td>0.05</td>
<td>7.95</td>
<td>7.90</td>
<td>−1.27</td>
<td>7.98</td>
</tr>
</tbody>
</table>

\( \tau_{I-T} = 15 \text{ min} \)

<table>
<thead>
<tr>
<th>Instant effect dose</th>
<th>Imaging dose (Gy)</th>
<th>Treatment dose (Gy)</th>
<th>DU-145</th>
<th>H460</th>
<th>AGO-1522b</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Protracted effective dose</td>
<td>Difference (%)</td>
<td>Protracted effective dose</td>
<td>Difference (%)</td>
<td>Protracted effective dose</td>
</tr>
<tr>
<td>1</td>
<td>0.05</td>
<td>0.95</td>
<td>–</td>
<td>–</td>
<td>1.00</td>
</tr>
<tr>
<td>2</td>
<td>0.05</td>
<td>1.95</td>
<td>1.98</td>
<td>−0.76</td>
<td>2.00</td>
</tr>
<tr>
<td>4</td>
<td>0.05</td>
<td>3.95</td>
<td>3.97</td>
<td>−0.86</td>
<td>3.99</td>
</tr>
<tr>
<td>8</td>
<td>0.05</td>
<td>7.95</td>
<td>7.89</td>
<td>−1.37</td>
<td>7.98</td>
</tr>
</tbody>
</table>

\( \tau_{I-T} \), imaging-to-treatment time.

Table 4. Instant vs protracted effect for DU-145, H460 and AGO-1522b cells incorporating the dose into the plan.
Table 5. Instant vs protracted effect for DU-145, H460 and AGO-1522b cells without incorporating the dose into the plan.

<table>
<thead>
<tr>
<th>Instant effect dose</th>
<th>Imaging dose (Gy)</th>
<th>Treatment dose (Gy)</th>
<th>DU-145</th>
<th>H460</th>
<th>AGO-1522b</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Protracted effective dose</td>
<td>Difference (%)</td>
<td>Protracted effective dose</td>
</tr>
<tr>
<td>1</td>
<td>0.05</td>
<td>1</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>2</td>
<td>0.05</td>
<td>2</td>
<td>2.01</td>
<td>0.73</td>
<td>2.01</td>
</tr>
<tr>
<td>4</td>
<td>0.05</td>
<td>4</td>
<td>4.00</td>
<td>0.13</td>
<td>4.02</td>
</tr>
<tr>
<td>8</td>
<td>0.05</td>
<td>8</td>
<td>7.94</td>
<td>−0.79</td>
<td>8.02</td>
</tr>
</tbody>
</table>

\( \tau_{I-T} = 7.5 \text{ min} \)

<table>
<thead>
<tr>
<th>Instant effect dose</th>
<th>Imaging dose (Gy)</th>
<th>Treatment dose (Gy)</th>
<th>DU-145</th>
<th>H460</th>
<th>AGO-1522b</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Protracted effective dose</td>
<td>Difference (%)</td>
<td>Protracted effective dose</td>
</tr>
<tr>
<td>1</td>
<td>0.05</td>
<td>1</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>2</td>
<td>0.05</td>
<td>2</td>
<td>2.01</td>
<td>0.48</td>
<td>2.01</td>
</tr>
<tr>
<td>4</td>
<td>0.05</td>
<td>4</td>
<td>4.00</td>
<td>−0.05</td>
<td>4.02</td>
</tr>
<tr>
<td>8</td>
<td>0.05</td>
<td>8</td>
<td>7.93</td>
<td>−0.88</td>
<td>8.02</td>
</tr>
</tbody>
</table>

\( \tau_{I-T} = 15 \text{ min} \)

\( \tau_{I-T} \) imaging-to-treatment time.
Extrapolation of these in vitro and theoretical findings to the clinical context is restricted owing to the limitations of two-dimensional cell culture methods, which do not replicate the vascular architecture of complex tumours. In addition, the fact that only megavoltage imaging beams were used in this study may limit the applicability of the results to other types of verification imaging. However, the preliminary megavoltage dose represents a portal imaging dose, which is on the higher side of the doses received by image-guided radiotherapy. Delivering CBCT or even paired images from different directions will result in non-homogenous (non-uniform) doses across organs or cells.

This could be complicated further by differences in dose deposition from kilovoltage imaging compared with megavoltage imaging and other factors such as patient dimensions and the treatment site. Although all of these factors cannot be taken into account, it is important to study the effects with a known uniform dose, delivered in a controlled fashion, before further investigation into this complex area of radiotherapy. With such a paucity of data in the literature on imaging effects, the novel investigation into this complex area of radiotherapy is restricted owing to the limitations of two-dimensional cell culture methods, which do not replicate the clinical context.

CONCLUSIONS
For DU-145, H460 and AGO-1522b cells, incorporation of an imaging dose of 5 cGy with the prescribed treatment dose was not found to have a significant impact on cell survival, for clinically relevant imaging-to-treatment times of 7.5 or 15 min. These findings were in good agreement with theoretically modelled data, based on the Lea–Catcheside dose protraction factor. These data suggest that imaging dose incorporation should not be expected to impact on tumour control in an adverse manner, since no significant increase in cell survival was observed.

FUNDING
This work was supported by grants from Cancer Research UK [grant numbers: C1513/A7047 (KMP), C212/A11342 (SMcM, ARH) and C212/A12463 (AJG)].

ACKNOWLEDGMENTS
The authors wish to acknowledge financial support from Cancer Research UK. The authors also wish to acknowledge the help of Dr Denise Irvine.

REFERENCES

23. Lea DE, Catcheside DG. The mechanism of the induction by radiation of chromosome


